Alkermes (NASDAQ:ALKS) Releases Earnings Results

Alkermes (NASDAQ:ALKS) posted its quarterly earnings results on Wednesday. The company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.81 by $0.11, Zacks reports. Alkermes had a net margin of 22.15% and a return on equity of 24.92%. Alkermes updated its FY 2025 guidance to 1.030-1.210 EPS.

Alkermes Stock Performance

ALKS stock traded up $0.95 during mid-day trading on Wednesday, reaching $32.91. 476,058 shares of the stock traded hands, compared to its average volume of 1,500,044. Alkermes has a 52 week low of $22.90 and a 52 week high of $32.88. The company has a quick ratio of 3.03, a current ratio of 3.45 and a debt-to-equity ratio of 0.22. The firm has a market capitalization of $5.32 billion, a PE ratio of 16.87, a P/E/G ratio of 1.83 and a beta of 0.49. The business has a 50-day moving average of $30.11 and a two-hundred day moving average of $28.62.

Insider Activity at Alkermes

In other Alkermes news, Director Cato T. Laurencin sold 2,691 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $31.85, for a total value of $85,708.35. Following the completion of the sale, the director now owns 23,013 shares in the company, valued at approximately $732,964.05. This trade represents a 10.47 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Christian Todd Nichols sold 5,208 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $29.15, for a total value of $151,813.20. Following the sale, the senior vice president now owns 60,703 shares in the company, valued at approximately $1,769,492.45. This represents a 7.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 179,189 shares of company stock worth $5,723,518 in the last 90 days. 4.89% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research analysts have weighed in on ALKS shares. Mizuho upped their target price on Alkermes from $35.00 to $40.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. The Goldman Sachs Group dropped their price objective on Alkermes from $32.00 to $30.00 and set a “buy” rating on the stock in a report on Friday, October 25th. Cantor Fitzgerald reduced their target price on shares of Alkermes from $48.00 to $43.00 and set an “overweight” rating for the company in a research note on Friday, October 25th. HC Wainwright restated a “neutral” rating and set a $37.00 price target on shares of Alkermes in a research note on Friday, October 25th. Finally, Stifel Nicolaus raised shares of Alkermes from a “hold” rating to a “buy” rating and lifted their price objective for the company from $25.00 to $36.00 in a research note on Tuesday, November 5th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $36.33.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.